細胞・遺伝子治療臨床試験サービスの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

細胞・遺伝子治療臨床試験サービス市場の世界需要は、2023年の45億3,000万米ドルから2032年にはほぼ118億9,000万米ドルの市場規模に達すると推定され、調査期間2024-2032年のCAGRは11.32%です。

細胞・遺伝子治療臨床試験サービスは、遺伝子や細胞を改変して病気を管理・予防する革新的な治療の開発・試験を支援します。これらのサービスには、患者募集、規制遵守、治療薬の製造、臨床試験管理など様々な活動が含まれます。これらのサービスは、臨床試験が安全、倫理的、かつ効率的に実施されることを保証することにより、科学的ブレークスルーを実行可能な治療法に変換する上で極めて重要です。これらのサービスの提供者は、研究者、製薬会社、ヘルスケア機関と密接に協力し、細胞・遺伝子治療試験の複雑な状況を乗り切ることで、最終的には生命を救う新しい治療法を市場に送り出すことを目指しています。

市場力学

研究開発活動の急増と革新的な治療法に対する需要の高まりが、細胞・遺伝子治療臨床試験サービスの需要を後押ししています。企業や学術機関は、こうした画期的な治療法の開発に多額の資金を投じており、世界の臨床試験の急増につながっています。遺伝性疾患や慢性疾患の急増は、効果的な細胞・遺伝子治療の緊急性をさらに強調し、その開発をサポートする包括的な臨床試験サービスの必要性を促しています。ヘルスケアを変革する細胞・遺伝子治療の可能性は持続しており、臨床研究に対する持続的な関心と投資を促しています。細胞・遺伝子治療臨床試験サービスを推進するためには、業界利害関係者、規制機関、研究機関の協力が不可欠です。しかし、厳しい規制要件や複雑な倫理的配慮は、今後数年間の細胞・遺伝子治療臨床試験サービス市場の成長に影響を与える可能性があります。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは細胞・遺伝子治療臨床試験サービスの世界市場における各セグメントを包括的に評価するものでもあります。細胞・遺伝子治療臨床試験サービス産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける細胞・遺伝子治療臨床試験サービス市場の現在および将来の需要を明らかにする地域展望を取り上げます。さらに、本レポートでは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 細胞・遺伝子治療臨床試験サービス-産業分析

• イントロダクション-市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• 業界動向
• ポーターのファイブフォース分析
• 市場魅力度分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーのリスト
• マーケティングチャネル
  • ダイレクトマーケティング
  • インダイレクトマーケティング
  • マーケティングチャネル発展動向

第5章 細胞・遺伝子治療臨床試験サービスの世界市場分析：サービス別

• サービス別概要
• 実績データと予測データ
• サービス別分析
• 臨床試験デザイン・プランニング
• サプライ・ロジスティクスサービス
• 薬事・コンプライアンス
• データマネジメント・生物統計学
• 治験施設管理・モニタリング
• その他のサービス

第6章 細胞・遺伝子治療臨床試験サービスの世界市場分析：フェーズ別

• フェーズ別概要
• 実績データと予測データ
• フェーズ別分析
• フェーズI
• フェーズII
• フェーズIII
• フェーズIV

第7章 細胞・遺伝子治療臨床試験サービスの世界市場分析：適応症別

• 適応症別概要
• 実績データと予測データ
• 適応症別分析
• 腫瘍学
• 血液学
• 内分泌・代謝疾患
• 感染症
• 神経学
• 心血管疾患
• 筋骨格系疾患
• その他の適応症

第8章 細胞・遺伝子治療臨床試験サービスの世界市場分析：治療タイプ別

• 治療タイプ別概要
• 実績データと予測データ
• 治療タイプ別分析
• 遺伝子治療
• 細胞療法
• 遺伝子改変細胞療法

第9章 細胞・遺伝子治療臨床試験サービスの世界市場分析：最終用途別

• 最終用途別概要
• 実績データと予測データ
• 最終用途別分析
• 製薬・バイオテクノロジー企業
• 受託研究機関
• 学術・研究機関
• その他のエンドユーザー

第10章 細胞・遺伝子治療臨床試験サービスの世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋地域売上分析
  • 概要、実績と予測
  • アジア太平洋地域：セグメント別
  • アジア太平洋地域：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他アジア太平洋地域
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他ラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東とアフリカ

第11章 細胞・遺伝子治療臨床試験サービス企業の競合情勢

• 細胞・遺伝子治療臨床試験サービス市場の競合
• パートナーシップ/提携/合意
• 合併・買収
• 新製品上市
• その他の開発

第12章 企業プロファイル

• 上位企業の市場シェア分析
• 市場集中度
• Advarra
• Charles River Laboratories International Inc.
• Catalent Pharma
• ICON PLC
• IQVIA
• Medpace Inc.
• Novotech
• Precision Medicine Group LLC
• Parexel International
• Syneos Health
• Sharp Services LLC
• Thermo Fisher Scientific Inc.
• Worldwide Clinical Trials

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Service (USD MN)
• Clinical Trial Design & Planning Market Sales By Geography (USD MN)
• Supply & Logistics Services Market Sales By Geography (USD MN)
• Regulatory Affairs & Compliance Market Sales By Geography (USD MN)
• Data Management & Biostatistics Market Sales By Geography (USD MN)
• Site Management & Monitoring Market Sales By Geography (USD MN)
• Other Services Market Sales By Geography (USD MN)
• Analysis By Phase (USD MN)
• Phase I Market Sales By Geography (USD MN)
• Phase II Market Sales By Geography (USD MN)
• Phase III Market Sales By Geography (USD MN)
• Phase IV Market Sales By Geography (USD MN)
• Analysis By Indication (USD MN)
• Oncology Market Sales By Geography (USD MN)
• Hematology Market Sales By Geography (USD MN)
• Endocrine/metabolic Disorders Market Sales By Geography (USD MN)
• Infectious Diseases Market Sales By Geography (USD MN)
• Neurology Market Sales By Geography (USD MN)
• Cardiovascular Diseases Market Sales By Geography (USD MN)
• Musculoskeletal Disorders Market Sales By Geography (USD MN)
• Other indications Market Sales By Geography (USD MN)
• Analysis By Therapy Type (USD MN)
• Gene Therapy Market Sales By Geography (USD MN)
• Cell Therapy Market Sales By Geography (USD MN)
• Gene Modified Cell Therapy Market Sales By Geography (USD MN)
• Analysis By End-Use (USD MN)
• Pharmaceutical & Biotechnology Companies Market Sales By Geography (USD MN)
• Contract Research Organizations Market Sales By Geography (USD MN)
• Academic & Research Institutes Market Sales By Geography (USD MN)
• Other end-users Market Sales By Geography (USD MN)
• Global Cell & Gene Therapy Clinical Trial Services Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Cell & Gene Therapy Clinical Trial Services Report
• Market Research Process
• Market Research Methodology
• Global Cell & Gene Therapy Clinical Trial Services Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Service
• Market Attractiveness Analysis By Phase
• Market Attractiveness Analysis By Indication
• Market Attractiveness Analysis By Therapy Type
• Market Attractiveness Analysis By End-Use
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Service (USD MN)
• Clinical Trial Design & Planning Market Sales By Geography (USD MN)
• Supply & Logistics Services Market Sales By Geography (USD MN)
• Regulatory Affairs & Compliance Market Sales By Geography (USD MN)
• Data Management & Biostatistics Market Sales By Geography (USD MN)
• Site Management & Monitoring Market Sales By Geography (USD MN)
• Other Services Market Sales By Geography (USD MN)
• Global Market Analysis By Phase (USD MN)
• Phase I Market Sales By Geography (USD MN)
• Phase II Market Sales By Geography (USD MN)
• Phase III Market Sales By Geography (USD MN)
• Phase IV Market Sales By Geography (USD MN)
• Global Market Analysis By Indication (USD MN)
• Oncology Market Sales By Geography (USD MN)
• Hematology Market Sales By Geography (USD MN)
• Endocrine/metabolic Disorders Market Sales By Geography (USD MN)
• Infectious Diseases Market Sales By Geography (USD MN)
• Neurology Market Sales By Geography (USD MN)
• Cardiovascular Diseases Market Sales By Geography (USD MN)
• Musculoskeletal Disorders Market Sales By Geography (USD MN)
• Other indications Market Sales By Geography (USD MN)
• Global Market Analysis By Therapy Type (USD MN)
• Gene Therapy Market Sales By Geography (USD MN)
• Cell Therapy Market Sales By Geography (USD MN)
• Gene Modified Cell Therapy Market Sales By Geography (USD MN)
• Global Market Analysis By End-Use (USD MN)
• Pharmaceutical & Biotechnology Companies Market Sales By Geography (USD MN)
• Contract Research Organizations Market Sales By Geography (USD MN)
• Academic & Research Institutes Market Sales By Geography (USD MN)
• Other end-users Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Cell & Gene Therapy Clinical Trial Services Market is presumed to reach the market size of nearly USD 11.89 Billion by 2032 from USD 4.53 Billion in 2023 with a CAGR of 11.32% under the study period 2024-2032.

Cell and gene therapy clinical trial services support developing and testing innovative treatments that entail modifying genes or cells to manage or prevent diseases. These services encompass a variety of activities, including patient recruitment, regulatory compliance, manufacturing of therapeutic agents, and clinical trial management. They are crucial in translating scientific breakthroughs into viable therapies by ensuring trials are conducted safely, ethically, and efficiently. Providers of these services work closely with researchers, pharmaceutical companies, and healthcare institutions to navigate the complex landscape of cell and gene therapy trials, ultimately aiming to bring new, life-saving treatments to market.

MARKET DYNAMICS

The surge in research and development activities and the growing demand for innovative treatment options have propelled the demand for cell and gene therapy clinical trial services. Companies & academic institutions are spending heavily in advancing these groundbreaking therapies, leading to an upsurge in clinical trials worldwide. The spurring prevalence of genetic disorders & chronic diseases further underscores the urgency for effective cell and gene therapies, driving the need for comprehensive clinical trial services to support their development. The potential of cell & gene transformation to revolutionize healthcare persists, driving sustained interest and investment in clinical research. Collaborations between industry stakeholders, regulatory bodies, and research institutions are crucial for advancing cell and gene therapy clinical trial services. However, stringent regulatory requirements and complex ethical considerations may challenge the growth of the cell and gene therapy clinical trial services market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cell & Gene Therapy Clinical Trial Services. The growth and trends of Cell & Gene Therapy Clinical Trial Services industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cell & Gene Therapy Clinical Trial Services market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Service

• Clinical Trial Design & Planning
• Supply & Logistics Services
• Regulatory Affairs & Compliance
• Data Management & Biostatistics
• Site Management & Monitoring
• Other Services

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Indication

• Oncology
• Hematology
• Endocrine/metabolic Disorders
• Infectious Diseases
• Neurology
• Cardiovascular Diseases
• Musculoskeletal Disorders
• Other indications

By Therapy Type

• Gene Therapy
• Cell Therapy
• Gene Modified Cell Therapy

By End-Use

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutes
• Other end-users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell & Gene Therapy Clinical Trial Services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell & Gene Therapy Clinical Trial Services market include Advarra, Charles River Laboratories International Inc., Catalent Pharma, ICON PLC, IQVIA, Medpace Inc., Novotech, Precision Medicine Group LLC, Parexel International, Syneos Health, Sharp Services LLC, Thermo Fisher Scientific Inc., Worldwide Clinical Trials. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CELL & GENE THERAPY CLINICAL TRIAL SERVICES - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Service
  • 3.7.2 Market Attractiveness Analysis By Phase
  • 3.7.3 Market Attractiveness Analysis By Indication
  • 3.7.4 Market Attractiveness Analysis By Therapy Type
  • 3.7.5 Market Attractiveness Analysis By End-Use
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY SERVICE

• 5.1. Overview By Service
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Service
• 5.4. Clinical Trial Design & Planning Historic and Forecast Sales By Regions
• 5.5. Supply & Logistics Services Historic and Forecast Sales By Regions
• 5.6. Regulatory Affairs & Compliance Historic and Forecast Sales By Regions
• 5.7. Data Management & Biostatistics Historic and Forecast Sales By Regions
• 5.8. Site Management & Monitoring Historic and Forecast Sales By Regions
• 5.9. Other Services Historic and Forecast Sales By Regions

6. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY PHASE

• 6.1. Overview By Phase
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Phase
• 6.4. Phase I Historic and Forecast Sales By Regions
• 6.5. Phase II Historic and Forecast Sales By Regions
• 6.6. Phase III Historic and Forecast Sales By Regions
• 6.7. Phase IV Historic and Forecast Sales By Regions

7. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY INDICATION

• 7.1. Overview By Indication
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Indication
• 7.4. Oncology Historic and Forecast Sales By Regions
• 7.5. Hematology Historic and Forecast Sales By Regions
• 7.6. Endocrine/metabolic Disorders Historic and Forecast Sales By Regions
• 7.7. Infectious Diseases Historic and Forecast Sales By Regions
• 7.8. Neurology Historic and Forecast Sales By Regions
• 7.9. Cardiovascular Diseases Historic and Forecast Sales By Regions
• 7.10. Musculoskeletal Disorders Historic and Forecast Sales By Regions
• 7.11. Other indications Historic and Forecast Sales By Regions

8. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY THERAPY TYPE

• 8.1. Overview By Therapy Type
• 8.2. Historical and Forecast Data
• 8.3. Analysis By Therapy Type
• 8.4. Gene Therapy Historic and Forecast Sales By Regions
• 8.5. Cell Therapy Historic and Forecast Sales By Regions
• 8.6. Gene Modified Cell Therapy Historic and Forecast Sales By Regions

9. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY END-USE

• 9.1. Overview By End-Use
• 9.2. Historical and Forecast Data
• 9.3. Analysis By End-Use
• 9.4. Pharmaceutical & Biotechnology Companies Historic and Forecast Sales By Regions
• 9.5. Contract Research Organizations Historic and Forecast Sales By Regions
• 9.6. Academic & Research Institutes Historic and Forecast Sales By Regions
• 9.7. Other end-users Historic and Forecast Sales By Regions

10. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE CELL & GENE THERAPY CLINICAL TRIAL SERVICES COMPANIES

• 11.1. Cell & Gene Therapy Clinical Trial Services Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF CELL & GENE THERAPY CLINICAL TRIAL SERVICES INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Advarra
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Charles River Laboratories International Inc.
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Catalent Pharma
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. ICON PLC
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. IQVIA
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Medpace Inc.
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Novotech
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. Precision Medicine Group LLC
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. Parexel International
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Syneos Health
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments
• 12.13. Sharp Services LLC
  • 12.13.1 Company Overview
  • 12.13.2 Company Revenue
  • 12.13.3 Products
  • 12.13.4 Recent Developments
• 12.14. Thermo Fisher Scientific Inc.
  • 12.14.1 Company Overview
  • 12.14.2 Company Revenue
  • 12.14.3 Products
  • 12.14.4 Recent Developments
• 12.15. Worldwide Clinical Trials
  • 12.15.1 Company Overview
  • 12.15.2 Company Revenue
  • 12.15.3 Products
  • 12.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies